


Contents lists available at [ScienceDirect](#)

## Understanding Modern Vaccines: Perspectives in Vaccinology



## Biographies

**Paolo Bonanni, MD:** Paolo Bonanni is Full Professor of Hygiene in the Faculty of Medicine at the University of Florence, Italy. He is also Director of the University's postgraduate course on 'Vaccines and Vaccination Strategies' which was established in 2001 and has since been undertaken by over 500 Italian MDs. Professor Bonanni graduated in medicine and surgery in 1985 and gained two specialisations in hygiene and preventive medicine at the University of Genoa, Italy. From 1992 to 2000 he was Associate Professor in the Faculty of Medicine at the University of Florence. His scientific activity has covered the epidemiology and prevention of infectious diseases, particularly viral hepatitis, diphtheria, tetanus, pertussis, influenza, measles, rubella, varicella and, most recently, bacterial invasive diseases and HPV, including clinical trials and economic evaluation of vaccination strategies. Professor Bonanni has been a member of the National Vaccination Commission of the Italian Ministry of Health, and he acts as an expert consultant for the European Centre for Disease Prevention and Control (ECDC). He is standing advisor for the Viral Hepatitis Prevention Board (VHPB), an international independent committee of experts in viral hepatitis prevention. Professor Bonanni has received several grants from the Italian Ministry of Education, University and Research for projects



© 2011 Elsevier B.V. Open access under [CC BY-NC-ND license](#).



relating to vaccine-preventable infections and was responsible for a research unit in three EU-funded projects: ANTRES (antibiotic resistance in Latin America), EURO-HEPNET (feasibility of an EU network for surveillance of vaccine-preventable hepatitis) and VACSATC (vaccine safety, attitudes and training). Professor Bonanni has authored or co-authored 200 scientific papers published in international and national journals.

**Wen-Fang Cheng, MD, PhD:** Wen-Fang Cheng is a Professor at the Graduate Institute of Oncology at the National Taiwan University College of Medicine, and Gynaecologic Oncologist at the Department of Obstetrics and Gynecology, National Taiwan University Hospital. Professor Cheng received his medical degree and PhD from the National Taiwan University College of Medicine. He completed his fellowship in the Training Programme of Gynecologic Oncologists at the National Health Research Institute, Taiwan. Professor Cheng has also served as a Postdoctoral Fellow at the Department of Pathology, Johns Hopkins University School of Medicine, as well as an observer for the Kelly Gynecologic Oncology Service in the Department of Obstetrics and Gynecology at the Johns Hopkins Medical Institutions, Maryland, USA. He is a member of several national and international professional bodies, including the International Gynecologic Cancer Society, Taiwan Association of Gynecologic Oncology and the Taiwan Association of Obstetrics and Gynecology. Professor Cheng's clinical interests include the use of ultrasound, surgery and chemotherapy in the treatment of gynaecologic cancers. His current research interests focus on tumour immunology and tumour biology. The author of over 100 peer-reviewed articles in national and international medical journals, Professor Cheng has received several awards in recognition of his innovative work in gynaecologic cancers such as cervical, uterine and ovarian carcinoma.



**Anthony Cunningham, MBBS, MD:** Tony Cunningham is Director of the Westmead Millennium Institute for Medical Research at the Westmead Hospital and of the Centre for Virus Research in Sydney, Australia. He is also Professor of Research Medicine and Sub-Dean (Research) at the Western Clinical School at the University of

Sydney. Professor Cunningham is also Director of the Australian Centre for HIV and Hepatitis Virology Research which is directly funded by the Australian Department of Health. He trained in infectious diseases, clinical virology and virology research at the University of Melbourne, Australia, and as a Postdoctoral Fellow at Stanford University, USA. Professor Cunningham's major research interests are in HIV and herpes simplex virus biology and immunology, especially in relation to the development of vaccines and microbicides. He has also published numerous original and review articles on epidemiology, antiviral therapy and vaccines for herpes simplex and varicella/zoster viruses, has participated in many international round-table meetings and often acts as a consultant for global pharma on these topics. Professor Cunningham has published more than 250 peer-reviewed primary scientific articles and 50 invited reviews or chapters in various journals or books. His publications have been cited over 7000 times.

**Nathalie Garçon, PharmD, PhD:** Nathalie Garçon is Vice President and Head of Global Adjuvant Centre for Vaccine Development at GSK Biologicals. Following the successful completion of two PhDs, one in biological pharmacy and the other in immunotoxicology and immunopharmacology, Dr Garçon moved to the UK for 1 year as a Postdoctoral Research Fellow at the Royal Free Hospital in London, undertaking research on liposomes in vaccines. She then moved to the USA where she spent 4 years at Baylor College of Medicine in Houston, Texas, first as a Postdoctoral Research Fellow, then as Assistant Professor, working on vaccine delivery systems and immunopotentiators. Dr Garçon joined SmithKline Beecham Biologicals – now GlaxoSmithKline Biologicals – in 1990, where she set up and led the vaccine adjuvant and formulation group. She provides leadership within GSK Biologicals in the field of adjuvants, from discovery to registration and commercialisation of adjuvanted vaccines. Dr Garçon's expertise in vaccinology extends from research to manufacturing, in particular immunology, adjuvant and formulation technologies, analytical methods, animal experimentation and toxicology/safety evaluation and testing. She has authored over 40 papers and book chapters, and holds more than 200 patents.





**Oberdan Leo, PhD:** Professor Oberdan Leo is Full Professor at the Université Libre de Bruxelles (ULB), Belgium, where he teaches Immunology and Cellular Biology at the Faculté des Sciences and has directed a research group at the Laboratory of Animal Physiology. Professor Leo is also Assistant Professor at the Université de Mons, Belgium. Since 1999, he has served as President of the Belgian Immunological Society. Professor Leo's major research interests focus on the relationship between metabolism and the inflammatory response and the analysis of T helper subset differentiation pathways. His contributions in these areas have resulted in more than 115 publications in top-ranked journals including *Nature Medicine*, the *Journal of Experimental Medicine*, *Proceedings of the National Academy of Sciences (USA)* and the *Journal of Immunology*. In 2004 GSK Biologicals initiated a public–private partnership with the ULB and the Walloon Region which supports the Institute for Medical Immunology and Professor Leo has been a consultant for the company for several years.



**Geert Leroux-Roels, MD, PhD:** Geert Leroux-Roels is Professor of Medicine and founding Director of the Center for Vaccinology at Ghent University and Hospital, Belgium. After obtaining his medical degree in 1976 from Ghent University, he trained in internal medicine while performing doctoral research on enzyme-immunoglobulin complexes in the Laboratory of Clinical Pathology at Ghent University Hospital. Over the past 25 years, Professor Leroux-Roels and his team have been studying the human immune response towards the hepatotropic viruses, HBV and HCV, and have made an important contribution to the understanding of mechanisms of non-responsiveness to hepatitis B vaccines. Since the discovery of HCV in 1989, he and his team have been examining the human immune response to this virus in order to understand the mechanisms underlying resolution and persistence. Professor Leroux-Roels' fascination with viruses and immunity has led to a growing interest and involvement in clinical vaccine evaluation. In the past two decades, more than 100 novel and improved vaccines and a series of innovating adjuvant systems have been clinically evaluated at the Center for Vaccinology. He is the author or co-author



of numerous articles published in international peer-reviewed journals, including *The Lancet*, *Hepatology* and *Vaccine*.

**José Ignacio Santos, MD, MSc:** José Ignacio Santos is Professor and Head of the Infectious Diseases Unit at the Department of Experimental Medicine, School of Medicine, National Autonomous University of Mexico. Professor Santos completed his medical and paediatric training at Stanford University, USA, and clinical immunology and infectious diseases training at the University of Utah, USA. Prior to his current appointment, Professor Santos was General Director at the Hospital Infantil de México Federico Gómez (2004–2009). From 1997–2004 he was Director of Mexico's National Infant and Adolescent Health Program and Immunization Program as well as Mexico's liaison member of the Advisory Committee on Immunization Practices of the Centers for Disease Control and Prevention. Professor Santos' research and public health interests have focused on paediatric infectious diseases and the evaluation and introduction of new vaccines. He works with several international health agencies including the International Center for Diarrheal Research (ICDDRDB); the Measles Working Group of the Strategic Advisory Group of Experts (SAGE, the principal advisory group to the World Health Organization [WHO] for vaccines and immunisation); the Pediatric Dengue Vaccine Initiative (PDVI), and the Data and Safety Monitoring Board for the WHO's Measles Aerosol Project. Professor Santos is past President of the Mexican and Pan-American Infectious Diseases Societies, a Fellow of the Infectious Diseases Society of America (IDSA) and a member of the advisory group of Pediatric Global Research Priorities (PGRP) of the American Academy of Pediatrics. He has authored or co-authored 270 peer-reviewed publications.

**Lawrence R Stanberry, MD, PhD:** Lawrence Stanberry is the Reuben S Carpentier Professor and Chairman of the Department of Pediatrics at the College of Physicians and Surgeons at Columbia University, USA, and Pediatrician-in-Chief of the New York Presbyterian Morgan Stanley Children's Hospital, USA. Professor Stanberry is an internationally recognised authority on vaccine development and viral diseases. He has served on numerous



advisory and review panels including Chair of the Vaccine Study Section and the Pediatrics Review Panel at the National Institutes of Health (NIH). Professor Stanberry has received research funding from the NIH, the Centers for Disease Control and Prevention, numerous vaccine, pharmaceutical and biotech companies, and the Bill and Melinda Gates Foundation. His areas of research include the development of prophylactic and therapeutic vaccines and his laboratory provided the first experimental evidence to support the concept of vaccine immunotherapy for the treatment of persistent viral infections. Professor Stanberry has authored over 200 scientific articles. He is the Co-editor (with Dr David Bernstein) of the textbook *Sexually Transmitted Diseases: Vaccines, Prevention, and Control* published by Academic Press Ltd, London (2000) and Co-editor (with Dr Alan Barrett) of the comprehensive textbook *Vaccines for Biodefense and Emerging and Neglected Diseases* published by Elsevier (London) in 2009.



**Peter L Stern, PhD:** Peter L Stern is Head of the Immunology Group at Cancer Research UK's Paterson Institute for Cancer Research at the University of Manchester. Professor Stern trained at University College, London, UK, obtaining his BSc and PhD. He has previously held research positions as staff scientist at the MRC Molecular Biology Laboratory, Cambridge, UK, European Molecular Biology Organization Fellow at the University of Uppsala, Sweden, Cancer Research Campaign Fellow and Junior Research Fellow at Linacre College, University of Oxford, UK, lecturer at the Medical School, University of Liverpool, UK, and Visiting Professor at the Free University of Amsterdam, The Netherlands. The theme of Professor Stern's research has been the investigation of shared properties of developmental tissues and cancer cells with a view to identifying new targets for diagnosis, prognosis or therapy. This focus and application at the translational interface has enabled ideas to transfer successfully from the bench to the clinic. Examples include an MVA-based 5T4 oncofoetal antigen vaccine and a 5T4 antibody-based superantigen therapy, both of which are now in phase III clinical trials. In the field of HPV, Professor Stern's activities have been directly related to the development of prophylactic and

therapeutic treatments for patients with HPV-associated anogenital disease. This has included the design and delivery of clinical and laboratory analyses of numerous clinical trials of vaccines and other immunotherapies.

**Richard Strugnell, MD, PhD:** Richard Strugnell is Professor of Microbiology in the Department of Microbiology and Immunology at The University of Melbourne, Australia. Professor Strugnell obtained his PhD in microbiology from Monash University, Australia in 1985, then undertook postdoctoral training in Australia and the UK, before taking up an academic post at Melbourne in 1991. His research interests are in bacterial pathogenesis, particularly the antibacterial immune responses that occur during natural infection, and in response to vaccination. Professor Strugnell's research focus is enteric bacteria including *Salmonella*, *Klebsiella* and *Helicobacter*, and in recent years he has investigated the roles of mucosal antibodies and T cells in disease prevention and in the pathological response to infection. His research on bacterial pathogenesis is leveraged to identify vaccine targets that can be delivered using adjuvanted or living vaccine delivery systems to elicit protective immune responses. Professor Strugnell receives funding support from the National Health and Medical Research Council of Australia and was a member of a team supported by the Gates Foundation's Grand Challenges in Global Health to develop a recombinant *Salmonella* delivery platform for the developing world.



**Terapong Tantawichien, MD:** Terapong Tantawichien is Professor in the Division of Infectious Diseases, Department of Medicine at Chulalongkorn University, Thailand. Professor Tantawichien received his medical degree from the same university and is board-certified in internal medicine and infectious diseases. His main scientific and research interests include rabies vaccination, adolescent and adult immunisation (such as HPV, pertussis and influenza), dengue in adults and infections in immunocompromised hosts. Professor Tantawichien has held positions at King Chulalongkorn Memorial Hospital and Kuzell Institute, California Pacific Medical Center, San Francisco, USA. He is former Secretary-General of the Infectious Diseases Association of



Thailand and is currently Chief of Division of Infectious Diseases and Deputy Chairman for Academic Affairs, Department of Medicine at Chulalongkorn University. Professor Tantawichien is also Assistant Director at the Queen Saovabha Memorial Institute in Bangkok, Thailand, and Deputy Chairman of the scientific committee of the Royal College of Physicians of Thailand. In 2001, he was the recipient of the first Young Investigator Award from the Infectious Diseases Association of Thailand. Professor Tantawichien is the author or co-author of numerous articles published in international peer-reviewed journals, including *The Lancet*, *Vaccine* and *Clinical Infectious Diseases*.



**Fred Zepp, MD, PhD:** Fred Zepp is Medical Director and Chairman of the Children's Hospital, Johannes Gutenberg University Mainz, Germany. He obtained his medical degree as a Research Fellow and undertook his residency in the Department of Paediatrics at the same university, where he was appointed Head of Paediatric Immunology and Infectiology in 1985. After working as a Research Fellow at the Institute for Immunology in Basel, Switzerland, Professor Zepp qualified as a paediatrician. His research focuses on cell-mediated immune responses to vaccines and candidate vaccines in infants and adults, immune responses to acute respiratory tract infection in children and immunology of the newborn. Professor Zepp has held many professional posts, including Attending Physician and Assistant Professor of Paediatrics at Johannes Gutenberg University Mainz. He is former Chair of the Association for Paediatric Immunology and current Chair of the advisory board of the 'Preventive Medicine in Paediatrics' Foundation. Professor Zepp is also a member of the scientific advisory board of the German Medical Association and last year was appointed President of the German Society of Paediatric and Adolescent Medicine. He has published more than 100 original papers and reviews.